Johnson Johnson Initiates Pivotal Global Phase 3 Clinical Tr...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
NEW BRUNSWICK, New Jersey, Sept. 23, 2020 /PRNewswire-AsiaNet/ -- -- First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.SJohnson & Johnson (NYSE: JNJ) (the Company) today announced the laun...
Authors: LATEST ASIANET NEWS RELEASES